FDA Identifies Two Bulk Drug Substances Not Included on 503B Bulks List

Summary

The FDA is evaluating substances for inclusion on the 503B Bulks List, which would allow outsourcing facilities to compound drug products with certain exemptions, and has identified ephedrine sulfate and hydroxychloroquine sulfate as not meeting the clinical need criteria at this time.